

Daftar Pustaka

- [1] T. Ren Lu, "Personalized Cancer Therapy: A Perspective," *Clin. Exp. Pharmacol.*, vol. 04, no. 02, 2014.
- [2] R. Article and I. C. Therapy, "EC CANCER Review Article Individualized Cancer Therapy, what is the Next Generation?," vol. 6, pp. 286–297, 2018.
- [3] M. F. Aziz, "Gynecological cancer in Indonesia," *Journal of Gynecologic Oncology*, vol. 20, no. 1. pp. 8–10, Mar-2009.
- [4] GLOBOCAN, "Estimated Number of Cancer Cases in 2018, Worldwide, Females aged 25-69," *International journal of cancer*, 2018. [Online]. Available: http://gco.iarc.fr/today/online-analysis-pie?v=2018&mode=cancer&mode_population=continents&population=900&populations=&key=total&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=5&ages_group%5B%5D=13&nb_items=7&group_can. [Accessed: 03-Oct-2019].
- [5] B. A. Chabner and T. G. Roberts, "Chemotherapy and the war on cancer," *Nature Reviews Cancer*, vol. 5, no. 1. pp. 65–72, Jan-2005.
- [6] N. Carelle, E. Piotto, A. Bellanger, J. Germanaud, A. Thuillier, and D. Khayat, "Changing patient perceptions of the side effects of cancer chemotherapy," *Cancer*, vol. 95, no. 1, pp. 155–163, Jul. 2002.
- [7] A. Coates *et al.*, "On the receiving end-patient perception of the side-effects of cancer chemotherapy," *Eur. J. Cancer Clin. Oncol.*, vol. 19, no. 2, pp. 203–208, 1983.
- [8] M. De Boer-Dennert *et al.*, "Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists," *Br. J. Cancer*, vol. 76, no. 8, pp. 1055–1061, 1997.
- [9] "Understanding Your Diagnosis." [Online]. Available: <http://www.cancer.org/content/cancer/en/treatment/understanding-your-diagnosis.html>. [Accessed: 14-Sep-2019].
- [10] D. Longley and P. Johnston, "Molecular Mechanisms of Drug Resistance," *J. Pathol.*, vol. 205, no. Cml, pp. 275–292, 2005.
- [11] K. Lingfei, Y. Pingzhang, L. Zhengguo, G. Jianhua, and Z. Yaowu, "A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers," *Cancer Lett.*, vol. 130, no. 1–2, pp. 93–101, Aug. 1998.
- [12] R. N. Rao, "Targets for cancer therapy in the cell cycle pathway," *Current Opinion in Oncology*, vol. 8, no. 6. Lippincott Williams and Wilkins, pp. 516–524, 1996.
- [13] S. Vilar, G. Cozza, and S. Moro, "Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery," *Curr. Top. Med. Chem.*, vol. 8, no. 18, pp. 1555–1572, Dec. 2008.
- [14] S. K. Singh, N. Dessalew, and P. V. Bharatam, "3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors," *Eur. J. Med. Chem.*, vol. 41, no. 11, pp. 1310–1319, 2006.
- [15] S. Kumar Singh, N. Dessalew, and P. Bharatam, "3D-QSAR CoMFA Study on Oxindole Derivatives as Cyclin Dependent Kinase 1 (CDK1) and Cyclin Dependent Kinase 2 (CDK2) Inhibitors," *Med. Chem. (Los. Angeles)*, vol. 3, no. 1, pp. 75–84, 2006.
- [16] P. Lan, W. N. Chen, G. K. Xiao, P. H. Sun, and W. M. Chen, "3D-QSAR and docking studies on pyrazolo[4,3-h]quinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors," *Bioorganic Med. Chem. Lett.*, vol. 20, no. 22, pp. 6764–6772, 2010.
- [17] T. Chen and T. He, "xgboost : eXtreme Gradient Boosting," *R Packag. version 0.4-2*, pp. 1–4, 2015.
- [18] R. P. Sheridan, W. M. Wang, A. Liaw, J. Ma, and E. M. Gifford, "Extreme Gradient Boosting as a Method for Quantitative Structure-Activity Relationships," *J. Chem. Inf. Model.*, vol. 56, no. 12, pp. 2353–2360, Dec. 2016.
- [19] Y. Qi, "Ensemble Machine Learning," *Ensemble Mach. Learn.*, pp. 307–323, 2012.

- [20] "ChEMBL." [Online]. Available: https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CDK2_inhibitor. [Accessed: 03-Dec-2019].
- [21] N. M. O'Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch, and G. R. Hutchison, "Open Babel: An Open chemical toolbox," *J. Cheminform.*, vol. 3, no. 10, p. 33, Oct. 2011.
- [22] I. Kurniawan, M. Rosalinda, and N. Ikhsan, "Implementation of ensemble methods on QSAR Study of NS3 inhibitor activity as anti-dengue agent," *SAR QSAR Environ. Res.*, vol. 00, pp. 0–16, 2020.
- [23] J. H. Friedman, "Stochastic gradient boosting," *Comput. Stat. Data Anal.*, vol. 38, no. 4, pp. 367–378, 2002.
- [24] Y. Saeys, I. Inza, and P. Larrañaga, "A review of feature selection techniques in bioinformatics," *Bioinformatics*, vol. 23, no. 19, pp. 2507–2517, 2007.
- [25] Y. L. Pavlov, "Random forests," *Random For.*, pp. 1–122, 2019.
- [26] Y. Freund and R. E. Schapire, "A decision-theoretic generalization of on-line learning and an application to boosting BT - Computational learning theory," *Comput. Learn. theory*, vol. 904, no. Chapter 2, pp. 23–37, 2005.
- [27] C. E. Brodley and M. A. Friedl, "Decision tree classification of land cover from remotely sensed data," *Remote Sens. Environ.*, vol. 61, no. 3, pp. 399–409, 1997.
- [28] J. R. Quinlan, "Induction of decision trees," *Mach. Learn.*, vol. 1, no. 1, pp. 81–106, 1986.
- [29] L. Breiman, *Classification and regression trees*. 2017.
- [30] S. Boughorbel, F. Jarray, and M. El-Anbari, "Optimal classifier for imbalanced data using Matthews Correlation Coefficient metric," *PLoS One*, vol. 12, no. 6, pp. 1–17, 2017.
- [31] T. Fawcett, "An introduction to ROC analysis," *Pattern Recognit. Lett.*, vol. 27, no. 8, pp. 861–874, Jun. 2006.
- [32] A. A. Miranda, Y. A. Le Borgne, and G. Bontempi, "New routes from minimal approximation error to principal components," *Neural Process. Lett.*, vol. 27, no. 3, pp. 197–207, 2008.